Lisata Therapeutics, Inc. (LSTA)
Lisata Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Lisata Therapeutics, Inc. (LSTA) is a Biotechnology company based in US with a market capitalization of $20.4M. Free cash flow was negative at -$16M. This page tracks LSTA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 26 employees · IPO Mar 1, 1999
Valuation
Valuation & price
$3.17as of May 17, 2026· -37.1% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.37
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$20.4M
Market cap
—
Revenue growth (YoY)
14.1%
Gross margin
-$16M
Free cash flow (USD)
-$16M
Net debt
Net cash position
4.3%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2024 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 11, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 24, 2026Filing
Merger Agreement Termination
- 8-K eventJul 17, 2026Filing
Merger Agreement Amendment
- 8-K eventJun 9, 2026Filing
Merger Agreement Amendment
- 8-K eventJun 1, 2026Filing
Tender Offer Update
- 8-K eventMay 29, 2026Filing
Merger Agreement
- Quarterly reportMay 11, 2026Filing
10-Q Filed
- 8-K eventMay 4, 2026Filing
Merger Agreement Amendment
- Annual reportApr 28, 2026Filing
10-K Filed
- 8-K eventApr 15, 2026Filing
Tender Offer Extension
- 8-K eventApr 3, 2026Filing
Tender Offer Extension
Questions
Frequently asked questions
What is Lisata Therapeutics, Inc.'s market cap?
Lisata Therapeutics, Inc. (LSTA) has a market capitalization of $20.4M.
What is LSTA's P/E ratio?
A meaningful P/E ratio is not available for LSTA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is LSTA's price-to-book (P/B) ratio?
LSTA trades at 1.37 times book value per share.
Are insiders buying LSTA stock?
SEC Form 4 filings show no open-market insider buys at Lisata Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.